Literature DB >> 8433683

Alveolar rhabdomyosarcoma with the t(2;13): cytogenetic findings and clinicopathologic correlations.

E C Douglass1, D N Shapiro, M Valentine, S T Rowe, A J Carroll, R B Raney, A H Ragab, S M Abella, D M Parham.   

Abstract

We describe here the clinical and pathologic features associated with a specific translocation, t(2;13), in alveolar rhabdomyosarcoma. Tumor specimens from 14 patients with a t(2;13)-positive alveolar rhabdomyosarcoma were studied for cytogenetic-clinicopathologic correlations. Three patients had occult primary tumors; nine patients had primary tumors of the trunk (mediastinal, pelvic, or rectal). The presence of the t(2;13) was ascertained from examination of tumor involved bone marrow in ten patients who had widespread metastatic disease at the time of diagnosis. Marrow involvement was so extensive in three cases that they were initially diagnosed as acute leukemia. Response to therapy was poor, with only five patients achieving a complete response. Twelve patients have died of their disease at a median survival time of 6 months from diagnosis and one is living with recurrent disease; only one patient survives free of disease.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8433683     DOI: 10.1002/mpo.2950210202

Source DB:  PubMed          Journal:  Med Pediatr Oncol        ISSN: 0098-1532


  13 in total

1.  A comparison of MyoD1 and fetal acetylcholine receptor expression in childhood tumors and normal tissues: implications for the molecular diagnosis of minimal disease in rhabdomyosarcomas.

Authors:  S Gattenloehner; B Dockhorn-Dworniczak; I Leuschner; A Vincent; H K Müller-Hermelink; A Marx
Journal:  J Mol Diagn       Date:  1999-11       Impact factor: 5.568

2.  Rhabdomyosarcoma: molecular diagnostics of patients classified by morphology and immunohistochemistry with emphasis on bone marrow and purged peripheral blood progenitor cells involvement.

Authors:  L Krsková; M Mrhalová; D Sumerauer; R Kodet
Journal:  Virchows Arch       Date:  2005-12-20       Impact factor: 4.064

3.  The fetal form of the acetylcholine receptor distinguishes rhabdomyosarcomas from other childhood tumors.

Authors:  S Gattenloehner; A Vincent; I Leuschner; S Tzartos; H K Müller-Hermelink; T Kirchner; A Marx
Journal:  Am J Pathol       Date:  1998-02       Impact factor: 4.307

Review 4.  Clinical aspects of alveolar rhabdomyosarcoma with translocation t(1;13)(p36;q14) and hypotetraploidy.

Authors:  B Gunawan; L Füzesi; B Granzen; U Keller; R Mertens; G Steinau; V Schumpelick
Journal:  Pathol Oncol Res       Date:  1999       Impact factor: 3.201

Review 5.  Genomic characteristics of soft tissue sarcomas.

Authors:  Fredrik Mertens; Ioannis Panagopoulos; Nils Mandahl
Journal:  Virchows Arch       Date:  2009-02-03       Impact factor: 4.064

Review 6.  Myogenin and MyoD1 expression in paediatric rhabdomyosarcomas.

Authors:  N J Sebire; M Malone
Journal:  J Clin Pathol       Date:  2003-06       Impact factor: 3.411

Review 7.  The inconvenience of convenience cohorts: rhabdomyosarcoma and the PAX-FOXO1 biomarker.

Authors:  Abby R Rosenberg; Stephen X Skapek; Douglas S Hawkins
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-05-07       Impact factor: 4.254

8.  Multiplex RT-PCR assay for the differential diagnosis of alveolar rhabdomyosarcoma and Ewing's sarcoma.

Authors:  J R Downing; A Khandekar; S A Shurtleff; D R Head; D M Parham; B L Webber; A S Pappo; M G Hulshof; W P Conn; D N Shapiro
Journal:  Am J Pathol       Date:  1995-03       Impact factor: 4.307

9.  Fusion of the Paired Box 3 (PAX3) and Myocardin (MYOCD) Genes in Pediatric Rhabdomyosarcoma.

Authors:  Ioannis Panagopoulos; Ludmila Gorunova; Kristin Andersen; Marius Lund-Iversen; Svetlana Tafjord; Francesca Micci; Sverre Heim
Journal:  Cancer Genomics Proteomics       Date:  2021 Nov-Dec       Impact factor: 4.069

10.  Detection of the PAX3-FKHR fusion gene in paediatric rhabdomyosarcoma: a reproducible predictor of outcome?

Authors:  J Anderson; T Gordon; A McManus; T Mapp; S Gould; A Kelsey; H McDowell; R Pinkerton; J Shipley; K Pritchard-Jones
Journal:  Br J Cancer       Date:  2001-09-14       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.